ACLX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACLX exhibits severe financial distress despite a strong technical trend and recent insider selling. The Piotroski F-Score of 1/9 indicates extremely weak financial health, with negative profitability metrics across all dimensions—operating margin at -3850.24%, ROE at -53.42%, and a revenue decline of -89.20% YoY. The absence of an Altman Z-Score raises bankruptcy risk concerns, while the Graham Number and intrinsic value are unavailable, suggesting no reliable defensive valuation. The stock trades at a massive premium with a Price/Sales of 300.17 and Forward P/E of -71.60, reflecting speculative growth expectations rather than fundamentals.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACLX vs LLY: Head-to-Head Comparison
This page compares Arcellx, Inc. (ACLX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.